For kids suffering from diabeticketoacidosis (DKA), researcherssuggest an alternative treatment: thefast-acting insulin Humalog.
In a study that took place betweenJune 2001 and June 2003, 60episodes of DKA with a bloodglucose level of 300 mg/dl wererecorded. Of the 60 episodes, 30were treated every two hours with0.15 units per kilogram (translate tounits) of Humalog. The other 30 casesreceived continuous intravenousRegular insulin (CIRI).
Respectively, capillary glucose levelsdecreased by 252.2 mg/dl and 46.8mg/dl in the Humalog and CIRIgroups, prompting the researchersto conclude that DKA treatment witha subcutaneous fast-acting insulinanalog represents a “cost-effectiveand technically simplified procedurethat precludes intensive care unitadmission.”
—Diabetes Care, August 2004